Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer
- 389 Downloads
Interleukin-35 (IL-35) has recently been implicated in tumor immunity. The aim of this study was to explore the clinical role of plasma IL-35 in patients with non-small cell lung cancer (NSCLC). Plasma collected from 106 patients with NSCLC cases and 78 healthy controls (HC) were subjected to IL-35 enzyme-linked immunosorbent assay (ELISA) and relationships between plasma IL-35 levels and clinical characteristics were evaluated. The correlation of IL-35 and overall survival was analyzed using Kaplan–Meier method. The prognostic value of IL-35 was tested using univariate and multivariate analysis. Circulating IL-35 levels were significantly higher in the NSCLC group in comparison with the HC group (21.37 ± 11.55 pg/ml vs. 10.09 ± 5.32 pg/ml, p < 0.001). Correlation analysis by subgroup indicated that plasma IL-35 correlated positively with tumor TNM stage (p < 0.001) and lymph node metastases (p < 0.0001). Using a cutoff level of 20.26 pg/ml (median value), IL-35 showed an inverse correlation with overall survival. Univariate and multivariate analysis indicated that plasma IL-35 was an independent prognostic factor for NSCLC patients. Circulating IL-35 in NSCLC patients significantly increased. IL-35 is a promising potential biomarker in prognostication of clinical outcome of NSCLC patients and the regulation of IL-35 expression may provide a new target for the treatment of NSCLC patients.
KeywordsNon-small cell lung cancer IL-35 Tumor marker Prognosis
This study was supported by grants from the Ministry of Science and Technology of China (973 projects) (No. 2012CB917104) and the National Natural Science Foundation of China (Nos. 81172853 and 81201605), Shanghai Municipal Commission of Health and Family Planning (No. XYQ2011040).
Conflicts of interest
- 3.Heist RS, Engelman JA. SnapShot: non-small cell lung cancer. Canc Cell. 2012;21(3):448.e2. doi: 10.1016/j.ccr.2012.03.007.
- 4.Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European lung cancer working party. J Clin Oncol Offic J Am Soc Clin Oncol. 1995;13(5):1221–30.CrossRefGoogle Scholar
- 7.Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007;37(11):3021–9. doi: 10.1002/eji.2007378101.CrossRefPubMedGoogle Scholar
- 12.Devergne O, Coulomb-L’Hermine A, Capel F, Moussa M, Capron F. Expression of Epstein-Barr virus-induced gene 3, an interleukin-12 p40-related molecule, throughout human pregnancy: involvement of syncytiotrophoblasts and extravillous trophoblasts. Am J Pathol. 2001;159(5):1763–76. doi: 10.1016/s0002-9440(10)63023-4.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Poleganov MA, Bachmann M, Pfeilschifter J, Muhl H. Genome-wide analysis displays marked induction of EBI3/IL-27B in IL-18-activated AML-derived KG1 cells: critical role of two kappaB binding sites in the human EBI3 promotor. Mol Immunol. 2008;45(10):2869–80. doi: 10.1016/j.molimm.2008.01.021.CrossRefPubMedGoogle Scholar
- 15.Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, et al. Identification of Epstein-Barr virus-induced gene 3 as a novel plasma and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res. 2011;17(19):6272–86. doi: 10.1158/1078-0432.ccr-11-0060.CrossRefPubMedGoogle Scholar